Document is current
Any future updates will be listed below
-
Authors
Chen, Xiupeng https://orcid.org/0000-0001-5916-3953
Xie, Qing
Nath, Sarah J.
Tang, Mojiao
Ma, Hong
Günes, Yasemin Özgür https://orcid.org/0000-0002-2112-127X
Sharma, Tapan https://orcid.org/0000-0003-2495-2236
Liu, Hao
Cui, Mengtian
Du, Ailing
Lu, Mengjia
Liu, Sophia Y.
Wassamon, Boonying
Xu, Mengyao https://orcid.org/0009-0001-2468-8941
Wu, Joseph Yunxi
Su, Qin
Fitzgibbons, Timothy P.
Liu, Jinghua
Wan, Fang
Kumanan, Veena
He, Ran
Ma, Yijie
Yang, Jun
Gray-Edwards, Heather L. https://orcid.org/0000-0002-7856-3159
Gallagher, Thomas L. https://orcid.org/0000-0001-6381-6902
Tai, Phillip W. L. https://orcid.org/0000-0001-7409-8344
Gao, Guangping https://orcid.org/0000-0003-0097-9012
-
Funding
Funding for this research was provided by:
Canbridge Pharm partially supports the study through a Sponsor research agreement.
- License Information
-
More Information
Article History
Received: 17 June 2025
Accepted: 6 May 2026
First Online: 23 May 2026
Competing interests
: Q.X., H.M., G.G. and J.X. are inventors of a patent application filed by the UMass Chan Medical School on SMA gene therapy. G.G. is a scientific co-founder of Voyager Therapeutics, Adrenas Therapeutics, AAVAA Therapeutics, and Aspa Therapeutics and holds equity in these companies. P.T., G.G. and J.X. are inventors of patents related to AAV-based gene therapy, some of which were licensed to commercial entities. Y.M. and J.Y. are employees of CANbridge Pharmaceuticals. Y.M. and J.Y. hold equity and/or stock options in CANbridge Pharmaceuticals. All other authors declare no competing interests.
